Azactam, Cayston(aztreonam)
Azactam, Aztreonam, Cayston, Emblaveo (aztreonam) is a small molecule pharmaceutical. Aztreonam was first approved as Azactam on 1986-12-31. It is used to treat bacterial infections, cellulitis, endometritis, intraabdominal infections, and pseudomonas infections amongst others in the USA. It has been approved in Europe to treat cystic fibrosis and respiratory tract infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Azactam, Aztreonam, Cayston (discontinued: Azactam, Aztreonam)
CombinationsEmblaveo
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Aztreonam
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| AZACTAM | Bristol Myers Squibb | N-050580 RX | 1986-12-31 | 2 products, RLD, RS |
| CAYSTON | Gilead Sciences | N-050814 RX | 2010-02-22 | 1 products, RLD, RS |
Show 2 discontinued
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| S0073 | Injection, aztreonam, 500 mg |
Clinical
Clinical Trials
70 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pseudomonas infections | D011552 | EFO_0001076 | A41.52 | — | 2 | 4 | 1 | 4 | 11 |
| Bronchiolitis obliterans | D001989 | EFO_0007183 | J44.81 | — | — | — | 1 | — | 1 |
| Bronchiolitis | D001988 | — | — | — | — | — | 1 | — | 1 |
| Bronchiolitis obliterans syndrome | D000092122 | — | D89.811 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fibrosis | D005355 | — | — | — | 3 | 9 | — | 6 | 18 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | 3 | 9 | — | 6 | 18 |
| Pseudomonas aeruginosa | D011550 | NCBITaxon_287 | — | — | 1 | 2 | — | 2 | 5 |
| Bronchiectasis | D001987 | — | J47 | — | 2 | 2 | — | — | 4 |
| Infections | D007239 | EFO_0000544 | — | — | 1 | 2 | — | 1 | 4 |
| Communicable diseases | D003141 | — | — | — | 1 | 2 | — | 1 | 4 |
| Respiratory aspiration | D053120 | EFO_1001839 | — | — | — | 1 | — | 1 | 2 |
| Respiratory tract infections | D012141 | — | J06.9 | — | — | 1 | — | — | 1 |
| Burkholderia infections | D019121 | EFO_1001280 | — | — | — | 1 | — | — | 1 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Aztreonam |
| INN | aztreonam |
| Description | Aztreonam, sold under the brand name Azactam among others, is an antibiotic used primarily to treat infections caused by gram-negative bacteria such as Pseudomonas aeruginosa. This may include bone infections, endometritis, intra abdominal infections, pneumonia, urinary tract infections, and sepsis. It is given by intravenous or intramuscular injection or by inhalation.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@H]1[C@H](NC(=O)/C(=N\OC(C)(C)C(=O)O)c2csc(N)n2)C(=O)N1S(=O)(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 78110-38-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL158 |
| ChEBI ID | 161680 |
| PubChem CID | 5742832 |
| DrugBank | DB00355 |
| UNII ID | G2B4VE5GH8 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Azactam – Elan Corporation
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 17,510 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
13,570 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use